Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection.

about

IFN-α-based treatment of patients with chronic HCV show increased levels of cells with myeloid-derived suppressor cell phenotype and of IDO and NOS.

P2860

Q39424862-27256985-C8C5-4930-952F-0107B4CD2635

P2860

Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection.

Item

http://www.wikidata.org/entity/Q38631256

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Dual daclatasvir and sofosbuvi ...... c hepatitis C virus infection.

@en

type

Item

label

Dual daclatasvir and sofosbuvi ...... c hepatitis C virus infection.

@en

prefLabel

Dual daclatasvir and sofosbuvi ...... c hepatitis C virus infection.

@en

P1476

Dual daclatasvir and sofosbuvi ...... c hepatitis C virus infection.

@en

P2093

Kris V Kowdley

http://www.w3.org/2001/XMLSchema#string

Vinay Sundaram

http://www.w3.org/2001/XMLSchema#string

P2860

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

Structures of hepatitis C virus nonstructural proteins required for replicase assembly and function

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection.

Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

P304

13-20

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/17474124.2016.1116937

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26560449

http://www.w3.org/2001/XMLSchema#string

P921

sofosbuvir

Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection.

about

P2860

P2860

Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921